# The Involvement of the Serotonergic System in Ketamine and Fluoxetine Combination-induced Cognitive Impairments in Mice

**Authors:** Emre Uyar, Meral Erdinç, İlker Kelle, Levent Erdinç, Uğur Şeker, Yusuf Nergiz

PMC · DOI: 10.5152/eurasianjmed.2024.23219 · The Eurasian Journal of Medicine · 2024-06-01

## TL;DR

This study explores how ketamine and fluoxetine together affect memory and brain health in mice, suggesting that serotonin plays a role in these effects.

## Contribution

The study reveals that the combination of ketamine and fluoxetine impairs memory consolidation and causes neurodegeneration in mice.

## Key findings

- Ketamine alone did not affect memory encoding, but combined with fluoxetine, it impaired memory consolidation.
- Fluoxetine negatively affected memory acquisition but not consolidation or retrieval when used alone.
- Histopathological changes were observed in all ketamine-treated groups, indicating neurodegeneration.

## Abstract

Glutamatergic N-methyl-D-aspartate (NMDA) receptors play vital roles in memory formation. Changes in the activity of these receptors influence memory processes. Ketamine is a noncompetitive NMDA receptor antagonist drug with promising mood-altering and pain-reducing effects in low doses. These effects are believed to be related to altered serotonergic transmission.

The present study investigated the involvement of the serotonergic system in low-dose ketamine administrations’ effects on memory acquisition, consolidation, and retrieval processes. Sixty-four male BALB/c mice were used in this experiment and separated into 8t groups. Mice were treated subchronically with a selective serotonin reuptake inhibitor, fluoxetine, and a serotonin depletion agent, p-chlorophenylalanine (pCPA). A serotonin antagonist, methiothepin, and ketamine were acutely administered 60 minutes before or after the behavioral tests. A passive avoidance (PA) test measured emotional memory acquisition, consolidation, and retrieval processes. Hippocampi malondialdehyde (MDA) levels were analyzed, and histopathological examinations were performed.

Ketamine alone did not significantly affect memory encoding processes in the PA test, while the ketamine–fluoxetine combination disrupted memory consolidation. Fluoxetine negatively affected the memory acquisition process, which was normalized during the consolidation and retrieval trials. Drug applications did not significantly alter hippocampal MDA levels. In all ketamine-applied groups, histopathologic alterations were evident.

Low-dose ketamine administration induces neurodegeneration, and it also impairs memory functions when combined with fluoxetine, indicating increased serotonergic transmission may be involved in the memory-impairing and neurotoxic effects of ketamine.

## Linked entities

- **Chemicals:** ketamine (PubChem CID 3821), fluoxetine (PubChem CID 3386), p-chlorophenylalanine (PubChem CID 4652), methiothepin (PubChem CID 4106), malondialdehyde (PubChem CID 10964)

## Full-text entities

- **Diseases:** pain (MESH:D010146), neurodegeneration (MESH:D019636), memory (MESH:D008569), neurotoxic (MESH:D020258), Cognitive Impairments (MESH:D003072)
- **Chemicals:** p-chlorophenylalanine (MESH:D010134), MDA (MESH:D008315), Ketamine (MESH:D007649), Fluoxetine (MESH:D005473), methiothepin (MESH:D008719), serotonin (MESH:D012701), NMDA receptor antagonist (-)
- **Species:** Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** BALB/c — Mus musculus (Mouse), Spontaneously immortalized cell line (CVCL_0184)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11332274/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11332274/full.md

## References

41 references — full list in the complete paper: https://tomesphere.com/paper/PMC11332274/full.md

---
Source: https://tomesphere.com/paper/PMC11332274